A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma
Objective: To compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventive or delayed treatment in neutropenia, completion rate of concurrent chemoradiotherapy and hospitalization rate in patients with esophageal squamous carcinoma...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-06-01
|
| Series: | Radiation Medicine and Protection |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666555722000223 |
| _version_ | 1797718238849662976 |
|---|---|
| author | Xin Dong Wei Deng Leilei Jiang Dan Yang Huiming Yu Dongming Li Anhui Shi Rong Yu Weihu Wang |
| author_facet | Xin Dong Wei Deng Leilei Jiang Dan Yang Huiming Yu Dongming Li Anhui Shi Rong Yu Weihu Wang |
| author_sort | Xin Dong |
| collection | DOAJ |
| description | Objective: To compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventive or delayed treatment in neutropenia, completion rate of concurrent chemoradiotherapy and hospitalization rate in patients with esophageal squamous carcinoma during definitive concurrent chemoradiotherapy. Methods: A total of 70 patients with esophageal squamous carcinoma in Peking University Cancer Hospital from January 2019 to December 2020, who received PEG-rhG-CSF during concurrent chemoradiotherapy, were enrolled in this retrospective analysis. There were 32 patients in the preventive group, and 38 patients in the delayed group. The incidence of neutropenia, completion rate of concurrent chemoradiotherapy and neutropenia-related hospitalization rate were compared between PEG-rhG-CSF preventive group and delayed group. Results: The incidence of severe neutropenia (Grades 3–4) in all patients was 31.4%. Comparison between preventive group and delayed group showed that the incidence of severe neutropenia was 6.3% and 39.4% (χ2 = 10.428, P = 0.001), respectively. In preventive group, the incidence of severe neutropenia was 3.7% and 20.0%, respectively, for primary prevention and secondary prevention of PEG-rhG-CSF (χ2 = 12.321, P = 0.001). The completion rate of concurrent chemoradiotherapy was 93.8% in the preventive group and 63.2% in the delayed group (χ2 = 9.220, P = 0.002). The incidence of treatment interruption was 25.7% in the whole group, 12.5% in the preventive group and 36.8% in the delayed group (χ2 = 5.389, P = 0.020). Seven patients (7/70, 10.0%) were hospitalized and treated with intravenous antibiotics for neutropenia, including 1 in the preventive group and 6 in the delayed group (P = 0.078). Conclusions: Prophylactic use of PEG-rhG-CSF during concurrent chemoradiotherapy for patients with esophageal squamous carcinoma can effectively reduce the incidence of neutropenia, ensure the safety of treatment, and improve the completion rate of concurrent chemoradiotherapy. |
| first_indexed | 2024-03-12T08:47:59Z |
| format | Article |
| id | doaj.art-9ad928adad6a4bb0bdc8f93cb41c9c2a |
| institution | Directory Open Access Journal |
| issn | 2666-5557 |
| language | English |
| last_indexed | 2024-03-12T08:47:59Z |
| publishDate | 2022-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Radiation Medicine and Protection |
| spelling | doaj.art-9ad928adad6a4bb0bdc8f93cb41c9c2a2023-09-02T16:24:25ZengElsevierRadiation Medicine and Protection2666-55572022-06-01328185A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinomaXin Dong0Wei Deng1Leilei Jiang2Dan Yang3Huiming Yu4Dongming Li5Anhui Shi6Rong Yu7Weihu Wang8Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaCorresponding author.; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaCorresponding author.; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, ChinaObjective: To compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventive or delayed treatment in neutropenia, completion rate of concurrent chemoradiotherapy and hospitalization rate in patients with esophageal squamous carcinoma during definitive concurrent chemoradiotherapy. Methods: A total of 70 patients with esophageal squamous carcinoma in Peking University Cancer Hospital from January 2019 to December 2020, who received PEG-rhG-CSF during concurrent chemoradiotherapy, were enrolled in this retrospective analysis. There were 32 patients in the preventive group, and 38 patients in the delayed group. The incidence of neutropenia, completion rate of concurrent chemoradiotherapy and neutropenia-related hospitalization rate were compared between PEG-rhG-CSF preventive group and delayed group. Results: The incidence of severe neutropenia (Grades 3–4) in all patients was 31.4%. Comparison between preventive group and delayed group showed that the incidence of severe neutropenia was 6.3% and 39.4% (χ2 = 10.428, P = 0.001), respectively. In preventive group, the incidence of severe neutropenia was 3.7% and 20.0%, respectively, for primary prevention and secondary prevention of PEG-rhG-CSF (χ2 = 12.321, P = 0.001). The completion rate of concurrent chemoradiotherapy was 93.8% in the preventive group and 63.2% in the delayed group (χ2 = 9.220, P = 0.002). The incidence of treatment interruption was 25.7% in the whole group, 12.5% in the preventive group and 36.8% in the delayed group (χ2 = 5.389, P = 0.020). Seven patients (7/70, 10.0%) were hospitalized and treated with intravenous antibiotics for neutropenia, including 1 in the preventive group and 6 in the delayed group (P = 0.078). Conclusions: Prophylactic use of PEG-rhG-CSF during concurrent chemoradiotherapy for patients with esophageal squamous carcinoma can effectively reduce the incidence of neutropenia, ensure the safety of treatment, and improve the completion rate of concurrent chemoradiotherapy.http://www.sciencedirect.com/science/article/pii/S2666555722000223Esophageal squamous carcinomaConcurrent chemoradiotherapyPegylated recombinant human granulocyte colony-stimulating factor |
| spellingShingle | Xin Dong Wei Deng Leilei Jiang Dan Yang Huiming Yu Dongming Li Anhui Shi Rong Yu Weihu Wang A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma Radiation Medicine and Protection Esophageal squamous carcinoma Concurrent chemoradiotherapy Pegylated recombinant human granulocyte colony-stimulating factor |
| title | A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma |
| title_full | A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma |
| title_fullStr | A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma |
| title_full_unstemmed | A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma |
| title_short | A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma |
| title_sort | retrospective study of pegylated recombinant human granulocyte colony stimulating factor peg rhg csf in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma |
| topic | Esophageal squamous carcinoma Concurrent chemoradiotherapy Pegylated recombinant human granulocyte colony-stimulating factor |
| url | http://www.sciencedirect.com/science/article/pii/S2666555722000223 |
| work_keys_str_mv | AT xindong aretrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT weideng aretrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT leileijiang aretrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT danyang aretrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT huimingyu aretrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT dongmingli aretrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT anhuishi aretrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT rongyu aretrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT weihuwang aretrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT xindong retrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT weideng retrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT leileijiang retrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT danyang retrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT huimingyu retrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT dongmingli retrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT anhuishi retrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT rongyu retrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma AT weihuwang retrospectivestudyofpegylatedrecombinanthumangranulocytecolonystimulatingfactorpegrhgcsfinpreventingneutropeniaduringdefinitiveconcurrentchemoradiotherapyinpatientswithesophagealsquamouscarcinoma |